Technical Analysis for MESO - Mesoblast Limited

Grade Last Price % Change Price Change
grade B 6.78 -1.09% -0.08
MESO closed down 1.09 percent on Friday, September 20, 2019, on 66 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical MESO trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Hammer Candlestick Bullish -1.09%
1,2,3 Pullback Bullish Bullish Swing Setup -1.09%
180 Bullish Setup Bullish Swing Setup -1.09%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.09%
Calm After Storm Range Contraction -1.09%
Upper Bollinger Band Walk Strength -4.51%

Older signals for MESO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Biotechnology Health Life Sciences Pharmaceutical Industry Stem Cells Therapeutic Products Cardiovascular Diseases Technology Platforms Diabetic Nephropathy Back Pain Mesoblast Host Diseases Regenerative Biomedicine
Is MESO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.78
52 Week Low 3.35
Average Volume 46,189
200-Day Moving Average 4.9743
50-Day Moving Average 5.3819
20-Day Moving Average 5.8055
10-Day Moving Average 6.6875
Average True Range 0.301
ADX 33.57
+DI 46.8703
-DI 20.0954
Chandelier Exit (Long, 3 ATRs ) 6.687
Chandelier Exit (Short, 3 ATRs ) 5.643
Upper Bollinger Band 7.8422
Lower Bollinger Band 3.7688
Percent B (%b) 0.74
BandWidth 70.164499
MACD Line 0.5554
MACD Signal Line 0.412
MACD Histogram 0.1433
Fundamentals Value
Market Cap 575.93 Million
Num Shares 84.9 Million
EPS -0.97
Price-to-Earnings (P/E) Ratio -6.99
Price-to-Sales 193.69
Price-to-Book 0.90
PEG Ratio -0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.11
Resistance 3 (R3) 7.14 7.06 7.06
Resistance 2 (R2) 7.06 6.98 7.05 7.04
Resistance 1 (R1) 6.92 6.92 6.88 6.89 7.02
Pivot Point 6.84 6.84 6.82 6.83 6.84
Support 1 (S1) 6.70 6.76 6.66 6.67 6.54
Support 2 (S2) 6.62 6.70 6.61 6.52
Support 3 (S3) 6.48 6.62 6.51
Support 4 (S4) 6.45